The hallmarks of cancer currently define the molecular mechanisms responsible for conferring specific tumor phenotypes. Recently, these characteristics were also connected to the status of the secretory pathway, thereby linking the functionality of this cellular machinery to the acquisition of cancer cell features. The secretory pathway ensures the biogenesis of proteins that are membrane-bound or secreted into the extracellular milieu and can control its own homeostasis through an adaptive signaling pathway named the Unfolded Protein Response (UPR). In the present review, we discuss the specific features of the UPR in various tumor types and the impact of the selective activation of this pathway on cell transformation, tumor development and aggressiveness.
Introduction
Tumor phenotypes including development and aggressiveness features can dramatically vary depending on the origin of tumor cells and context. The hallmarks of cancer defined by Hanahan and Weinberg [1] have helped to define these characteristics, which were also connected to the status of the secretory pathway (SP) [2, 3] . As a consequence this essential cellular component has taken significant importance in the acquisition of cancer cell features.
The SP ensures the biogenesis of proteins that are membrane-bound or secreted into the extracellular milieu. It is well accepted that approximately one-third of the polypeptides synthesized by a cell, enter the endoplasmic reticulum (ER), the first compartment of the SP [2, 3] . However, the quantity of proteins entering the secretory pathway fluctuates, depending on the cell physiology, function and specific microenvironment. For instance, the synthesis of antibodies, extracellular matrix proteins, membrane receptors or secretory cyto/chemokines is cell type specific and can impact the workload of the secretory machinery. Moreover, cell migration, differentiation or proliferation features can also create the demand for a higher need for protein secretion. Protein secretion fluctuations affect cell homeostasis, particularly cell amino acid, lipid and sugar metabolism and energy consumption. As such, a strong and reliable adaptive system is central for the cell to cope with the increased demand for protein folding in the ER. This adaptive system is named the Unfolded Protein Response (UPR). In this review, we provide specific examples illustrating how the diversification of UPR signals in many human cell types, particularly in secretory cells, could impact typical cancer initiation, tumor development and cancer cell aggressiveness.
The UPR transmits stress signals from the ER lumen to the rest of the cell by three different proteins called PERK, ATF6 and IRE1. PERK (PKR-like endoplasmic reticulum kinase) is a transmembrane protein with a specific kinase activity in its cytosolic domain. Its main substrate is the translation initiation factor eIF2 decrease in translation as well as a preferential translation of key proteins such as CHOP and GADD34, two factors directly involved in the cellular decisions of life or death. The transmembrane protein ATF6 (Activating Transcription Factor 6) is an ER transcription factor. Under stress conditions, ATF6 is exported to the Golgi apparatus, cleaved and released from its membrane attachment by the proteases S1P and S2P, to play its role as nuclear transcriptional activator. Finally, IRE1 (Inositol Requiring Enzyme 1), an ER resident type 1 transmembrane protein, has two enzymatic activities in its cytosolic domain: a serine/threonine kinase and an endoribonuclease activity. The endoribonuclease activity itself has two distinct molecular functions: i) it participates in the unconventional splicing of the A c c e p t e d M a n u s c r i p t 4 XBP1 transcription factor mRNA [4] ; ii) it degrades the mRNA of several secreted proteins, a process called RIDD (Regulated IRE1-Dependent Decay of RNA) [5] . The integration of signals from these three molecular pathways leads to a general transcription and translation reorientation, in favor of cell survival. Among the cellular processes regulated, the antioxidant capacity is increased, protein synthesis is decreased and the expression of ER chaperones/ER quality control proteins involved in protein folding (BiP, GRP94, CRT, PDIs) and in misfolded protein degradation is enhanced [6] [7] [8] . Finally, if ER homeostasis is not restored, ER stress can trigger apoptosis [9 , 10] (Figure 1) .
It is well established that differentiated cells such as neurons, blood cells, panc -cells, hepatocytes, all require a dedicated secretory pathway with appropriate specialized regulations [11] . In accordance with this, an increasing number of studies have shown a dependency of specific UPR components for the differentiation of particular cell types. For instance, the IRE1-plasma cells, or adipocytes [12 , 13 , 14 , 15 , 16] and disturbance of the PERK-ATF4
pathway triggers defects in oligodendrocytes, pancreatic and skeletal functions [17 , 18 , 19 , 20 , 21] .
A. The "secretory switch" in transformed cells
Most cancers have to cope with increasing fluxes of proteins through their secretory pathway.
This high secretory protein demand is caused by different hallmarks of cancer [2] and comprises all the processes that increase gene expression, in an unspecific manner, such as aneuploidy or the universal amplifier of transcription, MYC [22 , 23] . Hence, it is not surprising that aneuploidy was found to be associated to hypersensitivity to conditions interfering with protein synthesis and protein folding in yeast [24] and in human cancer cells [25] , and that MYC transformation requires a reliable secretory pathway to mediate its oncogenic potential [26] . Moreover, cell transformation can result in an increase in proliferation and metabolic demand, thereby leading to nutrient (i.e. glucose, amino acids) depletion and subsequent ER stress [27] . This means that during the cell transformation process, a "secretory switch" occurs and provides the transformed cells with novel secretory
properties, which will in turn impact on cell homeostasis and interaction with the stroma.
What are the consequences of the "secretory switch" and associated ER stress on tumor-stroma interactions? First, it can lead to microenvironment architecture destabilisation by remodelling of the extracellular matrix (ECM) through changes in ECM components abundance or matrix metalloproteases (MMPs) expression, and consequently, to an increase M a n u s c r i p t 5 in cancer dissemination and invasion [28 , 29] . Second, by modulating messenger (i.e. chemokines, cytokines) or contact/adhesion protein abundance (i.e. membrane receptors, integrins), the "secrotory switch" and associated ER stress can trigger cancer cell proliferation, migration or tumor angiogenesis. Third, it can lead to remodelling of the immune response and ER stress transmission in the tumor microenvironment [30, 31] . Fourth, it can modulate tumor immunogenicity by stimulating surface exposure of ER chaperones such as CRT [2, 32 , 33 ] (Figure 2) .
A.1. UPR involvement in gastrointestinal cancer initiation
The UPR is a central pathway for intestinal functions and differentiation, and the human gastrointestinal tract represents an interesting example of UPR specialization. This is well illustrated by the immunostaining of UPR components in the normal intestine, which showed that UPR activation occurs in a heterogeneous manner in intestinal cell populations. Indeed, GRP78 abundance appeared high in transit amplifying cells (TA), low in intestinal stem cells (ISC) and heterogenous in Paneth cells [34] . This suggests that the UPR could be induced with intestinal cell differentiation or could represent a pathway driving differentiation. One sufficient to trigger the loss of ISC stemness [34] . Considering that ISCs are thought to represent the cells of origin for most colorectal cancers (CRCs) [35] , this suggests that ER stress could have central implication for cancer initiation in the gastrointestinal tract.
Apart from the PERK/eIF2 the IRE1 branch. Indeed, the gastrointestinal tract is the main tissue where the two IRE1 [36] . Although the functions production in goblet cells [37] and in resistance to chemically induced colitis [36] . Moreover, XBP1 deficiency or expression of XBP1 variants was associated with Crohn's disease and ulcerative colitis [38] . Interestingly, IRE1
increased ER stress and inflammation of the intestine. A more recent report described the association between inflammatory bowel disease and tumorigenesis upon targeted deletion of XBP1 in the intestine [39] . A c c e p t e d M a n u s c r i p t 6 present ISC hyperproliferation observed in XBP1 deficient mice. Although one can ask the processes, the authors proposed expansion, in an XBP1-independent manner, which might leave room for an instrumental role --pathway was central for ER stress-induced inflammation [40] . Parallel to these mechanisms, and ER stress-induced intestinal inflammation. This was proposed as an explanation for the identification of mutations in autophagy components as risk factors in Crohn's disease [40] .
Finally, adding to the role of the UPR in intestinal epithelium, XBP1 was also identified as a susceptibility locus associated with oesophagus squamous cell carcinoma [41] and ER stress was shown to induce epithelial differentiation in precursor cells in the oesophagus [42] and also may be linked to Barett's syndrome [43] .
These studies provide good examples of i) how the UPR can fine-tune the entire functions and differentiation of the gastrointestinal epithelia by integrating information from the microenvironment and ii) how deregulation of this molecular pathway (XBP1 deletion)
can impact inflammatory bowel disease and gastrointestinal cancer initiation. downstream of ER stress [47] . Moreover, Imatinib resistance in CML K562 cells was bypassed when preventing the activation of the ATF6 arm of the UPR, thus demonstrating the strong interconnection of these pathways in acquisition of tumor cell phenotypes [48] .
A.2. UPR in blood cancers

B. UPR and EMT: an intricate relationship
Epithelial to Mesenchymal Transition (EMT) enables carcinoma cells to acquire key malignant traits such as migratory and invasion properties, induces stem cell properties and drug resistance [49 , 50 , 51] . Hallmarks of this transition are repression of epithelial markers, up-regulation of mesenchymal markers and changes in morphology. During EMT, the phenotype of carcinoma cells is largely modified, for example the loss of epithelial polarity and zonula adherens mediated by the down-regulation of E-cadherin. E-cadherin is a cell adhesion protein and its cytosolic domain is associated at the membrane of the cell tocatenin, which is a major player of the canonical WNT pathway [52] . Through EMT, diminution of E-cadherin leads to the release of -catenin, resulting in its nuclear translocation. In the nucleus, -catenin associates with transcription factors of the TCF/LEF family to regulate transcription of genes involved in EMT, migration and invasion. Activation of the UPR has been involved in a growing number of cancers [53] , but the link between UPR and EMT has been studied recently in breast cancers. Indeed, recent reports show an interrelationship between UPR signals and EMT, in a context specific manner [54 , 55 , 56] .
B.1. Activation of the UPR is instrumental for EMT induction
This phenomenon was first reported in thyroid cells, in which tunicamycin or thapsigargin triggered signaling by the proto-oncogene tyrosine kinase SRC, caused dedifferentiation through the down-regulation of thyroid specific genes and induced an EMT-like phenotype.
This included the change in the organization of the polarized epithelial monolayer, the formation of actin stress fibers, the loss of trans-epithelial resistance, the down-regulation of E-cadherin and the up-regulation of mesenchymal markers such as vimentin, -smooth actin,
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A c c e p t e d M a n u s c r i p t 8 1I collagen and SNAI1/SIP1. Moreover the use of PP2, a SRC kinase inhibitor prevented dedifferentiation and EMT, thus confirming the involvement of the SRC pathway [54] .
Moreover, the UPR (induced by tunicamycin or overexpression of a variant protein) in alveolar epithelial cells was shown to trigger the SRC and -catenin pathways [57] . Again, the use of PP2 also blocked the EMT and maintained the epithelial phenotype. Notably no increase in TGF-1, an important mediator of EMT, was observed in this report. Interestingly, in renal proximal tubular epithelial cells, thapsigargin induced an EMT whereas tunicamycin did not [58] . ER stressors that alter calcium fluxes between the ER lumen and the cytosol such as thapsigargin lead to an increased expression of TDAG51 and TGF-1. TDAG51 interacts with the cytoskeleton and induces shape changes as well as the activation of WNT signaling thereby leading to EMT. As such, overexpression of TDAG51 alone was able to induce an EMT phenotype in HK-2 cells. The serine/cysteine protease inhibitor SCCA1 is deregulated in many cancers associated with poor differentiation and aggressiveness. In mammary epithelial cells (MCF10A), overexpression of SCCA1 induces chronic UPR. This non-lethal chronic UPR activates NF-B that leads to IL-6 production, resulting in EMT-like phenotypes [59] . It has been recently reported that IL-6 signaling plays a critical role in driving EMT through cell autonomous inflammation [60 , 61] . In light of these reports, activation of UPR can lead to EMT trough several mechanisms including IL-6, SRC and/or WNT signaling, but how the UPR is triggered, either through alteration of calcium concentrations or increase of improperly folded proteins, might also determine the biological outcome. Thus, one might hypothesize that ER stressed cells enter dedifferentiation/EMT to change their phenotypes and consequently lower ER stress [57] .
B.2. EMT induces activation of the UPR in colorectal and breast carcinoma
Cells subjected to EMT are also known to display an important secretory phenotype notably by changes in ECM protein secretion [62 , 63] . This could represent a cause for ER stress and UPR activation. In colorectal carcinoma cells (SW480, HCT116), stabilization of HIF1 through CoCl 2 -mediated inhibition of proline hydroxylase, or serum starvation, induces EMT and the subsequent activation of the UPR [64] . This mechanism is in part dependent upon ZEB-1, which is the main factor for EMT in colorectal carcinoma cells and a transcriptional
repressor for E-cadherin [52 , 65 , 66] . In mammary epithelial cells, EMT induction by TWIST overexpression correlates with PERK constitutive activation [55] . Other branches of the UPR (i.e. IRE1
PERK activity attenuated cells' ability to migrate and to form tumor spheres, thereby indicating that PERK might be involved in EMT-dependent cell malignancy. In addition,
A c c e p t e d M a n u s c r i p t 9 PERK signaling in EMT dedifferentiated cells leads to constitutive activation of NRF2, a master regulator of cellular response to oxidative damage, causing these cells to become chemoresistant through expression of antioxidant enzymes and drug efflux pumps [67, 68 , 69] . These results might therefore explain the correlation observed between PERK activation status and highly aggressive and poorly differentiated breast cancer tumors. It is noteworthy that in tubular epithelial cells both EMT and UPR are activated simultaneously through reactive oxygen species (ROS) and SRC kinase-dependent pathways [70] .
C. Targeting UPR as a novel approach to treat EMT chemoresistant cells
As there is a hierarchical relationship between UPR and EMT it could allow the development of new treatment strategies. Indeed, in diseases where EMT is induced by UPR e.g. lung fibrosis, chronic kidney disease or breast cancer [57 , 58, 59 ] targeting the UPR or the downstream activated pathways (e.g. SRC, WNT) with inhibitors might be an efficient way to prevent cells from undergoing EMT. In vitro, results were already observed with PP2
targeting the SRC kinase and preventing both PC C13 cells (thyroid cells) and alveolar epithelial cells from undergoing an EMT [54, 57 ] . Currently, ER stress drugs are only used to treat multiple myeloma patients [71] , however because EMT is associated with chemoresistance and invasiveness [49 , 50 , 51] , there is a critical need to develop new approaches, therefore it might be very attractive to exploit the ER stress-sensitivity exhibited by cells subjected to EMT [64] . Indeed it was shown that in breast cancer cells several ER stressors such as tunicamycin, thapsigargin, DTT and A23187 render EMT undergoing cells more sensitive to cell death (up to 25 fold for thapsigargin). These treatment could even selectively eliminated EMT undergoing cells when co-cultivated with normal cells [55] . Also targeting the PERK pathway that is constitutively active in breast cancer [56 , 72] 
C.1. UPR control of glioblastoma phenotypes
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A c c e p t e d M a n u s c r i p t 10 Glioblastoma (GBM) is the most common primary brain tumor in humans and remains incurable [73] . Despite the therapeutic efforts made in recent years, mortality is still close to 100% at 5 years. Different factors are involved in GBM aggressiveness, among which angiogenesis and tumor cell invasion/infiltration are critical [74 , 75] . Moreover, the mesenchymal phenotype is another hallmark of tumor aggressiveness in GBM [76 , 77] .
Remarkably, a single UPR component, IRE1
GBM aggressiveness. Indeed, it was shown that expression of a dominant negative form of expression of extracellular matrix, angiogenesis, and inflammation proteins. This is in [78 , 79] east one driver mutation [78] -driven modulation of angiogenesis was attributed to the positive regulation of pro-angiogenic factors such as VEGF-A, IL--6 secretion [80, 81] and the cleavage of the mRNA codding for the circadian gene PERIOD1 [82] . Adding to its role in the regulation of angiogenesis, PERIOD1
-dependent GBM infiltration [82] substrate, the mRNA coding for the extracellular matrix protein SPARC was also found to be involved in modulation of GBM invasion ability in an autocrine fashion [83] . Taken together, these data underline that IRE1
control the phenotype, the physiology and the aggressiveness of GBM.
C.2. UPR in triple negative breast cancer
Triple negative breast cancers (TNBC) represent the most aggressive breast cancer subtype, with high rates of tumor recurrence and poor overall survival [84] . Although the lack of expression of the estrogen, progesterone and HER2 receptors clusters these tumors within the same group, they still comprise heterogeneous and poorly characterized breast cancers with no selective therapy [85] . Recently, a study by Chen and colleagues [86] revealed the contribution of the UPR to TNBC, in particular through the cross-talk with HIF-1 , a transcription factor previously shown to be of particular importance in the hypoxic response in TNBC. Chen and colleagues characterize a new molecular mechanism, XBP1s-dependent HIF-1 activation in TNBC, thereby indicating potential novel therapeutic strategies mediated through the inhibition of XBP1 in TNBC [87] . These observations could also be linked to the acquisition of a mesenchymal phenotype by breast tumor cells. Indeed, increased expression of XBP1 is associated with the progression of breast cancer and XBP1s is A c c e p t e d M a n u s c r i p t 11 significantly over-expressed in matched metastatic tumors, which can act as a major regulator of EMT through SNAIL signaling [88] . Moreover, as autophagy and UPR signaling also appear to be interconnected, combined chloroquine (CQ), a pharmacological inhibitor of autophagy, with other drugs known to act as ER stress enhancers (nelfinavir (an HIV protease inhibitor) and celecoxib (a cyclooxygenase-2 inhibitor) or its non-coxib analog 2,5-dimethylcelecoxib (DMC)) were tested in TNBC. Addition of CQ resulted in synergistic enhancement of tumor cell killing by ER stress aggravators in vitro and in vivo, thus opening novel therapeutic avenues for TNBC [89] .
D. Conclusions and future perspectives
Collectively, the afore-mentioned information sheds light on the intricate cancer signaling networks into which the UPR is involved. From this analysis it becomes evident that characterizing the UPR status in tumors might not only represent a good predictor of the disease outcome but also constitute an essential toolkit for better defining personalized treatments and following up treatment efficacy. As such, a thorough analysis of the UPR in tumors could be envisioned to firstly select the best and most relevant markers/predictors of tumor characteristics and then secondly to apply the most efficient targeted therapies to those tumors. Needless to say that in this context, therapies targeting the UPR itself could also be of interest either alone or as adjuvant therapies. In conclusion, the specificity of UPR signals and its impact on tumor phenotype represents an interesting avenue to better characterize carcinogenesis but also when documented in patients' tumors will constitute a novel basis for tumor typing and specialized treatments.
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